TickerFacts.

Qiagen N.V. (QGEN): Operating Cash Flow

Annual figures by period end, from SEC filings.

$654.33M
Year ended 2025-12-31
-2.9%
3-year compound annual growth
+7.4%
5-year compound annual growth
+7.5%
10-year compound annual growth
$715.26M2008-12-31: $173.00M2009-12-31: $217.00M2010-12-31: $250.75M2011-12-31: $244.78M2012-12-31: $244.88M2013-12-31: $258.96M2014-12-31: $287.96M2015-12-31: $317.50M2016-12-31: $341.60M2017-12-31: $286.78M2018-12-31: $359.50M2019-12-31: $330.84M2020-12-31: $457.81M2021-12-31: $639.00M2022-12-31: $715.26M2023-12-31: $459.45M2024-12-31: $673.55M2025-12-31: $654.33M$654.33M
2008-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31$654.33M-2.9%2026-03-20, From 2025-01-01
2024-12-31$673.55M+46.6%2026-03-20, From 2024-01-01
2023-12-31$459.45M-35.8%2026-03-20, From 2023-01-01
2022-12-31$715.26M+11.9%2025-03-31, From 2022-01-01
2021-12-31$639.00M+39.6%2024-03-11, From 2021-01-01
2020-12-31$457.81M+38.4%2023-03-13, From 2020-01-01
2019-12-31$330.84M-8.0%2022-03-14, From 2019-01-01
2018-12-31$359.50M+25.4%2021-03-05, From 2018-01-01
2017-12-31$286.78M-16.0%2020-03-02, From 2017-01-01
2016-12-31$341.60M+7.6%2019-03-06, From 2016-01-01
2015-12-31$317.50M+10.3%2018-03-06, From 2015-01-01
2014-12-31$287.96M+11.2%2017-03-06, From 2014-01-01
2013-12-31$258.96M+5.7%2016-02-29, From 2013-01-01
2012-12-31$244.88M0.0%2015-03-02, From 2012-01-01
2011-12-31$244.78M-2.4%2014-03-03, From 2011-01-01
2010-12-31$250.75M+15.6%2013-03-04, From 2010-01-01
2009-12-31$217.00M+25.4%2012-03-27, From 2009-01-01
2008-12-31$173.00Mn/a2011-03-21, From 2008-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Qiagen N.V. (QGEN)2025-12-31$654.33M-2.9%
Moderna, Inc. (MRNA)2025-12-31-$1.87Bn/m
Exelixis, Inc. (EXEL)2026-01-02$884.27M+26.3%
Neurocrine Biosciences Inc (NBIX)2025-12-31$782.70M+31.5%
Halozyme Therapeutics, Inc. (HALO)2025-12-31$651.56M+36.0%
Bio-Techne Corp (TECH)2026-06-30$292.07M+1.6%
Novavax Inc (NVAX)2025-12-31-$244.63Mn/m
BioCryst Pharmaceuticals Inc (BCRX)2025-12-31$347.37Mn/m
Repligen Corp (RGEN)2025-12-31$117.42M-33.1%

Compare QGEN, MRNA, EXEL, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗